Solventum Corporation (SOLV) receives a Roarable Rating of D (Sell) and flashes a Red SELL / AVOID warning (59/100 RQD Confidence). Our SEC filing scanner spotted paper earnings outpacing real operating cash flow (+288.9% (NI vs OCF)) while unpaid customer invoices grew—a classic sign to step aside until cash flow catches up.
Solventum Corporation (SOLV) surged +2.09% to $83.56 as options desks priced 55% call premium vs. 45% put protection around the $82 max-pain magnet. Accounting Warning: Paper earnings outpaced operating cash flow (+288.9% (NI vs OCF)) as receivables rose.
Solventum (SOLV) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
For questions about this article or underlying research, email help@trefis.com.
Analysts expect Solventum’s earnings to edge lower year-over-year when the company reports its third-quarter results next month.
While some companies burn cash to fuel expansion, others struggle to turn spending into sustainable growth. A high cash burn rate without a strong balance sheet can leave investors exposed to significant downside.
Solventum gains FDA clearance to combine Restrata Matrix with V.A.C. Therapy, potentially expanding wound care applications and supporting long-term growth.
Annual revenue, volume and price data for permanent crowns and bridges in Mexico from 2024 to 2036, with 2025 company shares for Ivoclar, Dentsply Sirona, Solventum, Shofu and Dentaurum.Dublin, Oct. 22, 2026 (GLOBE NEWSW
Elevance Health (ELV) delivered earnings and revenue surprises of +50.00% and +4.01%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Solventum (NYSE: SOLV), a leader in advanced wound healing, announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the combined use of Restrata™ Synthetic Electrospun Fiber Matr
Solventum (NYSE: SOLV), a leader in advanced wound healing, announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the combined use of Restrata™ Synthetic Electrospun Fiber
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +0.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on SOLV today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for SOLV. Explore sector supply chains on /butterfly.
Why SOLV Stock surged +2.09% Today — RQD Quant Desk Flash. Accounting Warning: Paper earnings outpaced operating cash flow (+288.9% (NI vs OCF)) as receivables rose.